Objectives.The best strategy for non-functioning, sporadic, G1-G2 pancreatic neuroendocrine tumors ≤2cm is unknown.An active surveillance is usually recommended.The PROMID and the CLARINET studies proved the value of somatostatin analogue (SSA) treatment in advanced gastro-entero-pancreatic neuroendocrine tumors.Aim of this study is to assess the value of SSA in PanNET≤2cm.Methods.We retrospectively collected data from 72 patients with sporadic non-functioning G1-G2 PanNETs≤2cm, that were either treated with somatostatin analogues (n=31) or underwent active surveillance (n=41) at our Institution.Results.At a median follow-up of 53.7 months, the median progression free survival was not reached in the treatment group versus an estimated PFS of 85 months in the control group (HR 0.11, p = 0.01), with a rate of progression or death up to 21.9% in the active surveillance group.Additionally, in the group of patients treated with somatostatin analogues the response rate was 16.1% with one complete response.Conclusions.Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogues in patients with sporadic, non-functionating G1-G2 PanNETs ≤2cm delaying tumor progression and distant spread in small lesions that sometimes may reveal unpredictable aggressiveness.
SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS
Inzani, Frediano;Rindi, Guido
2024-01-01
Abstract
Objectives.The best strategy for non-functioning, sporadic, G1-G2 pancreatic neuroendocrine tumors ≤2cm is unknown.An active surveillance is usually recommended.The PROMID and the CLARINET studies proved the value of somatostatin analogue (SSA) treatment in advanced gastro-entero-pancreatic neuroendocrine tumors.Aim of this study is to assess the value of SSA in PanNET≤2cm.Methods.We retrospectively collected data from 72 patients with sporadic non-functioning G1-G2 PanNETs≤2cm, that were either treated with somatostatin analogues (n=31) or underwent active surveillance (n=41) at our Institution.Results.At a median follow-up of 53.7 months, the median progression free survival was not reached in the treatment group versus an estimated PFS of 85 months in the control group (HR 0.11, p = 0.01), with a rate of progression or death up to 21.9% in the active surveillance group.Additionally, in the group of patients treated with somatostatin analogues the response rate was 16.1% with one complete response.Conclusions.Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogues in patients with sporadic, non-functionating G1-G2 PanNETs ≤2cm delaying tumor progression and distant spread in small lesions that sometimes may reveal unpredictable aggressiveness.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
